Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual MeetingGlobeNewsWire • Tuesday
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)GlobeNewsWire • 03/06/24
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateGlobeNewsWire • 02/13/24
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerGlobeNewsWire • 01/24/24
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital HyperinsulinismGlobeNewsWire • 01/23/24
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital HyperinsulinismGlobeNewsWire • 12/14/23
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)GlobeNewsWire • 12/13/23
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"Newsfile Corp • 11/24/23
Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric StudySeeking Alpha • 11/09/23
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital HyperinsulinismGlobeNewsWire • 10/17/23
Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated HyperinsulinismGlobeNewsWire • 10/11/23
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company ProgressGlobeNewsWire • 09/14/23
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital HyperinsulinismGlobeNewsWire • 06/27/23
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye DiseaseNewsfile Corp • 06/01/23
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company ProgressGlobeNewsWire • 05/11/23
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular EdemaGlobeNewsWire • 03/23/23
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical ExpertGlobeNewsWire • 03/08/23
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company ProgressGlobeNewsWire • 02/10/23
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular EdemaGlobeNewsWire • 12/15/22
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company ProgressGlobeNewsWire • 11/09/22